TechNavio's analysts forecast the Global Hepatitis C Drugs market to grow at a CAGR of 28 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of hepatitis C infection. The Global Hepatitis C Drugs market has also been witnessing the shift of treatments from multiple drug therapy to single drug therapy. However, the virus developing resistance to the drugs could pose a challenge to the growth of this market.
TechNavio's report, the Global Hepatitis C Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hepatitis C Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include GlaxoSmithKline plc, Merck & Co. Inc., Roche Holding Ltd., and Vertex Pharmaceuticals Ltd.